SCHEMBL11896372

SCHEMBL11896372

O[C@]12CCCO[C@@H]1CCC[C@H]2Nc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 6/20 0.47
ESR1 P03372 1/20 0.35
PGR P06401 1/20 0.35
HTR2A P28223 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TRPC5 Q9UL62 1/20 0.35
KCNH3 Q9ULD8 1/20 0.33
ALDH1A1 P00352 2/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
HPGD P15428 2/20 0.30
NPC1 O15118 1/20 0.30
TP53 P04637 1/20 0.30
POLB P06746 1/20 0.30
RAB9A P51151 1/20 0.30
DDB1 Q16531 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11896364 1.00 TRPA1 (0.47) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL11954706 1.00 TRPA1 (0.47) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL10438 0.89 TRPA1 (0.53) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL11896360 0.89 TRPA1 (0.53) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL11967563 0.86 TRPA1 (0.64) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL10059 0.86 TRPA1 (0.64) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL11967351 0.86 TRPA1 (0.64) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL15809978 0.86 TRPA1 (0.64) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL11967544 0.86 TRPA1 (0.64) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL2133 0.86 TRPA1 (0.64) TRPA1ESR1PGRHTR2ASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP claimed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US claimed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 TRPA1 1/4885ESR1 3872/4885PGR 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.